In 123 men with low-intermediate risk prostate cancer on active surveillance, monthly cholecalciferol 50,000 IU did not improve active therapy-free survival vs placebo (log-rank p=0.44); progression-free survival and adverse events were also similar.
RCTn = 123
Nair-Shalliker et al. High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD)